Despite decades of
awareness and prevention campaigns, heart disease remains the No. 1 cause of
death for both men and women, killing more than 600,000 Americans each year.
Roughly 49 percent of Americans have at least one of the three risk factors for
heart disease: high blood pressure, high LDL cholesterol and smoking, according
to the Center for Disease Control. What’s astounding is that an overwhelming
majority of heart disease is the result of poor lifestyle choices. While it’s
certainly nothing to celebrate, the statistics are keeping scientists on their
toes and companies like VistaGen in business.
VistaGen is an
innovative life sciences company leveraging its Human Clinical Trials in a Test
Tube™ technology platform to provide clinically relevant predictions of
potential toxicity of promising new drug candidates. One of VistaGen’s
particular areas of focus is on cardiovascular care.
It is estimated that
about one-third of all potential new drugs candidates fail in preclinical or
clinical development due to unexpected safety concerns. Countless human lives
have been lost because “promising” cardiovascular drugs were discontinued
because of late-stage failure. Using human heart cells derived from human
pluripotent stem cells (hPSCs), VistaGen’s technology is designed to address
potential toxicity of new cardiovascular drug candidates long before they are
ever tested in humans.
CardioSafe 3D™, the
company’s novel three-dimensional (3D) bioassay system, was developed to
identify safer drug rescue variants with reduced heart safety concerns, which
can be missed in animal models or in vitro cell culture testing currently used
by biotechnology and pharmaceutical companies.
VistaGen’s strategy
is to pair CardioSafe 3D™ with modern medicinal chemistry to build a pipeline
of novel, safer chemical variants (Drug Rescue Variants™) of once-promising
drug candidates that initially were developed by biotechnology and
pharmaceutical companies, but that were later abandoned due to the
aforementioned concerns.
The core goal is to
license or sell Drug Rescue Variants to biotechnology and pharmaceutical
companies for further development and commercialization. VistaGen believes its
strategy has the potential to substantially reduce drug development costs and
produce effective and safer drugs, which would inherently help save human
lives.
For more information
visit www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment